Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NUTEX InvestmentsBUD:NUTEX -0.77%18 Earnings Yield (Joel Greenblatt) % is 3.05% as of Dec. 2025. GuruFocus rates BUD:NUTEX with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, NUTEX Investments ranks worse than 99304.77% on this metric.
NUTEX Investments's Enterprise Value for the quarter that ended in Dec. 2025 was Ft-3,553.13 Mil.
NUTEX Investments's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was Ft-108.44 Mil. NUTEX Investments's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 3.05%.
The historical rank and industry rank for NUTEX Investments's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BUD:NUTEX'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -104.05 Med: -1.24 Max: 101.54
Current: 3.42
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of NUTEX Investments was 101.54%. The lowest was -104.05%. And the median was -1.24%.
BUD:NUTEX's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.07
vs BUD:NUTEX: 3.42
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. NUTEX Investments's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
NUTEX Investments Earnings Yield (Joel Greenblatt) % Related Terms
NUTEX Investments Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
NUTEX Investmentss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 3.05% mean?
NUTEX Investments (BUD:NUTEX) has a Earnings Yield (Joel Greenblatt) % of 3.05% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NUTEX Investments and its competitors. According to the industry distribution chart, NUTEX Investments ranks #999999 out of 1007 companies in the Drug Manufacturers industry.
Is NUTEX Investments' Earnings Yield (Joel Greenblatt) % too high?
NUTEX Investments' current Earnings Yield (Joel Greenblatt) % is 3.05%. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.07. NUTEX Investments' value of 3.05% is 0.7% below this industry median. Based on the distribution chart, NUTEX Investments ranks #999999 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NUTEX Investments has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #999999 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This places NUTEX Investments in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.07. NUTEX Investments' value of 3.05% is 0.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.07, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Earnings Yield (Joel Greenblatt) % of 3.05% is 0.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Earnings Yield (Joel Greenblatt) % is 3.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
NUTEX Investments (BUD:NUTEX) has a current Earnings Yield (Joel Greenblatt) % of 3.05%. The current Earnings Yield (Joel Greenblatt) % is 3.05% and 0.7% below the Drug Manufacturers industry median of 3.07. NUTEX Investments' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Earnings Yield (Joel Greenblatt) % is 3.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
18GF Score
Get the complete analysis for BUD:NUTEX
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
